Section 7(6) of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires clinical commissioning groups, NHS England and, with respect to their public health functions, local authorities to comply with the recommendations in this evaluation within 3 months of its date of publication.
NHS England has stated that it is able to meet all the conditions for reimbursement within 90 days with the exception of the research programme which will require longer to establish. It is expected that a national protocol for starting and stopping eculizumab for clinical reasons will be developed within 3 months of publication of this Guidance, on the basis of current evidence and practice, and subsequently updated as results from the research programme are available. No extension to the normal period was required.
NICE has not developed implementation tools but will work with NHS England to ensure implementation of the recommendations is monitored.